OTCMKTS:EKTAY - ELEKTA AB/ADR Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $13.66 +0.16 (+1.18 %) (As of 07/17/2018 08:00 AM ET)Previous Close$13.5001Today's Range$13.59 - $13.7052-Week Range$7.85 - $13.70Volume2,329 shsAverage Volume5,629 shsMarket Capitalization$4.98 billionP/E Ratio341.50Dividend Yield0.61%Beta0.48 Company ProfileAnalyst RatingsDividend HistoryEarnings HistoryHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; Monaco, a treatment planning system; Venezia, an applicator for treating gynecological cancer; and METRIQ, a cancer registry data solution. It also offers installation, implementation, training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden. Receive EKTAY News and Ratings via Email Sign-up to receive the latest news and ratings for EKTAY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Medical laboratories Sub-IndustryN/A SectorMedical SymbolOTCMKTS:EKTAY CUSIPN/A Webwww.elekta.com Phone46-8-587-254-00 Debt Debt-to-Equity Ratio0.59 Current Ratio1.26 Quick Ratio1.11 Price-To-Earnings Trailing P/E Ratio341.50 Forward P/E Ratio∞ P/E Growth3.66 Sales & Book Value Annual Sales$1.23 billion Price / Sales4.11 Cash Flow$0.2453 per share Price / Cash55.69 Book Value$2.10 per share Price / Book6.50 Profitability EPS (Most Recent Fiscal Year)$0.04 Net Income$14.30 million Net Margins5.80% Return on Equity9.70% Return on Assets3.23% Miscellaneous Employees3,681 Outstanding Shares368,590,000Market Cap$4,976.00 ELEKTA AB/ADR (OTCMKTS:EKTAY) Frequently Asked Questions What is ELEKTA AB/ADR's stock symbol? ELEKTA AB/ADR trades on the OTCMKTS under the ticker symbol "EKTAY." How often does ELEKTA AB/ADR pay dividends? What is the dividend yield for ELEKTA AB/ADR? ELEKTA AB/ADR declared a None dividend on Monday, March 5th. Stockholders of record on Friday, February 23rd will be paid a dividend of $0.04 per share on Thursday, March 15th. The ex-dividend date is Thursday, February 22nd. View ELEKTA AB/ADR's Dividend History. How were ELEKTA AB/ADR's earnings last quarter? ELEKTA AB/ADR (OTCMKTS:EKTAY) issued its earnings results on Wednesday, December, 4th. The company reported $0.07 earnings per share for the quarter. The firm earned $373.34 million during the quarter. ELEKTA AB/ADR had a return on equity of 9.70% and a net margin of 5.80%. View ELEKTA AB/ADR's Earnings History. When is ELEKTA AB/ADR's next earnings date? ELEKTA AB/ADR is scheduled to release their next quarterly earnings announcement on Thursday, July, 19th 2018. View Earnings Estimates for ELEKTA AB/ADR. What is the consensus analysts' recommendation for ELEKTA AB/ADR? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ELEKTA AB/ADR in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of ELEKTA AB/ADR's key competitors? Some companies that are related to ELEKTA AB/ADR include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Foundation Medicine (FMI), Genomic Health (GHDX), Natera (NTRA), RadNet (RDNT), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Enzo Biochem (ENZ), Celcuity (CELC), Miragen Therapeutics (MGEN), PotNetwork (POTN), Psychemedics (PMD) and Fulgent Genetics (FLGT). Who are ELEKTA AB/ADR's key executives? ELEKTA AB/ADR's management team includes the folowing people: Mr. Laurent Leksell, Founder & Chairman (Age 66)Dr. Richard Hausmann Ph.D., Pres & CEO (Age 58)Mr. Gustaf Salford, CFO & Exec. VP (Age 41)Mr. Steven Wort Steven Wort Has Chief Operating Officer Only, Chief Operating Officer (Age 55)Mr. John Lapré, Chief Technology Officer (Age 54) Has ELEKTA AB/ADR been receiving favorable news coverage? News stories about EKTAY stock have trended somewhat positive recently, according to Accern. The research firm rates the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. ELEKTA AB/ADR earned a media sentiment score of 0.21 on Accern's scale. They also assigned press coverage about the company an impact score of 46.14 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days. How do I buy shares of ELEKTA AB/ADR? Shares of EKTAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is ELEKTA AB/ADR's stock price today? One share of EKTAY stock can currently be purchased for approximately $13.66. How big of a company is ELEKTA AB/ADR? ELEKTA AB/ADR has a market capitalization of $4.98 billion and generates $1.23 billion in revenue each year. The company earns $14.30 million in net income (profit) each year or $0.04 on an earnings per share basis. ELEKTA AB/ADR employs 3,681 workers across the globe. How can I contact ELEKTA AB/ADR? ELEKTA AB/ADR's mailing address is P.O. Box 7593, Stockholm V7, SE-103 93. The company can be reached via phone at 46-8-587-254-00 or via email at [email protected] MarketBeat Community Rating for ELEKTA AB/ADR (OTCMKTS EKTAY)Community Ranking: 2.1 out of 5 ( )Outperform Votes: 86 (Vote Outperform)Underperform Votes: 117 (Vote Underperform)Total Votes: 203MarketBeat's community ratings are surveys of what our community members think about ELEKTA AB/ADR and other stocks. Vote "Outperform" if you believe EKTAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EKTAY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/17/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?